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NMDA ?R antagonists such as phencyclidine (PCP) and ketamine arewell ?known for their
abilitytoproduceschizophrenia ?likesymptomswhenadministeredacutely inbothhealthy
individuals(Krystaletal.,1994)orinremittedschizophreniapatients(Lahtietal.,1995),and
when administered chronically (Morris et al., 2005). Assessing the impact of these
antagonists on functional connectivity is also particularly pertinent given the suggested
central role for altered NMDA ?R mediated synaptic plasticity in the functional
dysconnectivityseeninschizophrenia(Stephanetal.,2006;2009).




greater correspondencewith the disease, but these are lesswell studied, particularly in
humans. For example, the ability of ketamine to reduce the auditorymismatch negative
(MMN) signal, in a similarway to that seen in schizophrenia patients (Umbrict& Krljes,
2005),mayresultfromalteredsynapticplasticityandconnectivityintheprojectionbetween
theauditoryandsuperiortemporalgyrus(Schmidtetal.,2013b),twobrainregionsstrongly
implicated in theauditoryhallucinationsexperiencedbyschizophreniapatients (Lawrieet
al., 2002). Furthermore, acute ketamine treatmenthasbeen shown to reduceprefrontal




2013b), suggesting that the ability of NMDA ?R antagonists to modulate functional
connectivitymaybedifferentunderbaselineand intask ?activatedsituations.Additionally,
timing also seems to be important as while acute subanaethetic ketamine treatment
increasesconnectivityatrest(Driesenetal.,2013b)thisappearstobedecreased24hours
after ketamine treatment (Scheidegger et al., 2012). The temporal relationship between
these alterations in connectivity and the symptoms exhibited needs to be more clearly
defined.Forexample,theacuteeffectsofketamineonbrainconnectivitymayrelatemore
directly to its ability to induce schizophrenia ?like symptoms, whereas the connectivity
alterations at 24 hours post ?ketamine treatment may relate more to its antidepressant
effects (Scheidegger et al., 2012, Driesen et al., 2013a ; 2013b). Furthermore, the
relationshipbetweenNMDA ?Rantagonistinducedalterationsinfunctionalconnectivityand
the stage of the disease needs to be carefully considered, as evidenced by recent data






































































































































































































































































































































































































































































































































































































































































































































Reduced Hippocampal ʹ PFC Connectivity 
Preclinical Model Reference Modality Summary 
Df(16)A+/- mutant mice 
(genetic risk model) 
Siggurdsson et al., 2010 EEG Reduced synchrony during 








Phillips et al., 2012 EEG Impaired phase locking in 
sleeping animals 
Belujon et al., 2013 Electrophysiology Reduced mPFC-evoked synaptic 
plasticity induced by high-






Sekar et al., 2013 rs-fMRI Reduced functional connectivity 
(correlation based) following 
subchronic memantine treatment 
Dawson et al., 2012 2-DG functional 
imaging 
Reduced connectivity (PLSR) 
following subchronic PCP 
treatment 
Dawson et al., 2014a 2-DG functional 
imaging 
Reduced connectivity (Graph 
Theory Measures) following 
subchronic PCP treatment 





Dawson et al., 2012 2-DG functional 
imaging 
Reduced thalamic-mPFC 
connectivity (PLSR) following 
subchronic PCP treatment 
Dawson et al., 2013 2-DG functional 
imaging 
Reduced PFC-AV/MD thalamus 
connectivity (PLSR) following 
subanaesthetic ketamine 
treatment 
Dawson et al., 2014a 2-DG functional 
imaging 
Reduced thalamic connectivity 
(Graph Theory Measures) 
following subchronic PCP 
treatment 
 
Table 1: Alterations in hippocampal-PFC and thalamic functional connectivity reported in 
preclinical models relevant to schizophrenia. 2-DG: 2-deoxyglucose; AV: anteroventral; MD: 
mediodorsal; EEG: electroencephalogram (electrodes) ; MIA: maternal immune activation; MAM: 
methylazoxymethanol acetate; rs-fMRI; resting state fMRI; PCP: phencyclidine; PLSR: partial least 
squares regression analysis; PFC: prefrontal cortex 
